{"id":"placebo-matched-to-ocrelizumab","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T12:29:45.049851","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo matched to ocrelizumab is an inert formulation designed to match the appearance, administration route, and schedule of ocrelizumab (an anti-CD20 monoclonal antibody) for blinded clinical trial purposes. It allows for comparison of ocrelizumab's efficacy and safety against a control without active drug effect. The matching ensures trial integrity by preventing bias from differences in injection appearance or frequency.","oneSentence":"This is a placebo control arm matched to ocrelizumab, the active comparator, and contains no pharmacologically active ingredient.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:53.952Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT04544449","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-26","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":985},{"nctId":"NCT07282574","phase":"PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-10","conditions":"Progressive Multiple Sclerosis","enrollment":360},{"nctId":"NCT04035005","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-08-12","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":1013},{"nctId":"NCT05123703","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-19","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":188},{"nctId":"NCT00676715","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-07-17","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":220},{"nctId":"NCT01412333","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09-20","conditions":"Relapsing Multiple Sclerosis","enrollment":835},{"nctId":"NCT01247324","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08-31","conditions":"Relapsing Multiple Sclerosis","enrollment":821},{"nctId":"NCT01194570","phase":"PHASE3","title":"A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03-02","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":735},{"nctId":"NCT03835728","phase":"PHASE2","title":"Efficacy of Ocrelizumab in Autoimmune Encephalitis","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-01-22","conditions":"Autoimmune Encephalitis","enrollment":3},{"nctId":"NCT00673920","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-04-24","conditions":"Rheumatoid Arthritis","enrollment":314},{"nctId":"NCT00406419","phase":"PHASE3","title":"A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2006-12-27","conditions":"Rheumatoid Arthritis","enrollment":1015},{"nctId":"NCT00476996","phase":"PHASE3","title":"A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-05-15","conditions":"Rheumatoid Arthritis","enrollment":836},{"nctId":"NCT02720120","phase":"PHASE1, PHASE2","title":"A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2005-10","conditions":"Rheumatoid Arthritis","enrollment":175}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matched to ocrelizumab","genericName":"Placebo matched to ocrelizumab","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}